LAVA Therapeutics NV
LAVA Therapeutics NV (LVTX): 6 pipeline candidates · ~31 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
31.0 months
D/E 3.09 · 2% dilution
Lead: Phase 1
6 candidates
N/A
N/A
A transparent, data-derived signal for LAVA Therapeutics NVacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$49.7M
Quarterly Burn
$4.9M
Runway
31.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| jnj-89853413 | Preclinical |
| lava-1207 | Phase 1 |
| lava-1266 | Phase 1 |
| lava-1427 | Phase 1 |
| lava-1433 | Preclinical |
| pf-8046052 | Phase 1 |
Frequently asked questions
How many drug candidates are in LAVA Therapeutics NV's pipeline?
LAVA Therapeutics NV (LVTX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is LAVA Therapeutics NV's lead drug candidate?
LAVA Therapeutics NV's most advanced tracked candidate is jnj-89853413 (Preclinical) for Cancer.
What is LAVA Therapeutics NV's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, LAVA Therapeutics NV has approximately 31.0 months of cash runway.
Who is the CEO of LAVA Therapeutics NV?
Stephen Hurly Stephen is the chief executive officer of LAVA Therapeutics NV (LVTX).
Get the full picture on LAVA Therapeutics NV
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.